Category Archives: Infringement

DC grant of SJ of no induced infringement affirmed, exclusion of expert report proper since Phigenix did not “timely disclose its narrowed infringement theory”

Phigenix, Inc. v. Genetech, Inc. Docket No. 2017-2617, 2018-1042 REYNA, BRYSON, STOLL September 5, 2019 Non-Precedential Brief Summary: DC grant of SJ of no induced infringement after exclusion of Phigenix’s expert report affirmed (e.g., “[w]ithout its expert report, Phigenix’s direct … Continue reading

Posted in Inducement to Infringe, Infringement, Uncategorized | Leave a comment

DC grant of SJ to Genentech of no induced infringement affirmed, exclusion of expert report proper since Phigenix did not “timely disclose its narrowed infringement theory”

Phigenix, Inc. v. Genetech, Inc. Docket No. 2017-2617, 2018-1042 REYNA, BRYSON, STOLL September 5, 2019 Non-Precedential Brief Summary: DC grant of SJ of no induced infringement after exclusion of Phigenix’s expert report affirmed (e.g., “[w]ithout its expert report, Phigenix’s direct … Continue reading

Posted in Inducement to Infringe, Infringement, Uncategorized | Leave a comment

Lilly’s Orange Book ‘209 patent regarding administration of pemetrexed not literally infringed, but infringed under DOE

Eli Lilly and Company v. Hospira, Inc., Dr. Reddy’s Laboratories Docket No. 2018-2126, -2127, -2128 LOURIE, MOORE, TARANTO August 9, 2019 Brief Summary: DC literal infringement decision reversed, but infringement under DOE affirmed. Summary: Hospira and Dr. Reddy’s (DRL) appealed … Continue reading

Posted in Claim Construction, Doctrine of equivalents, Generics / ANDA, Infringement, Method claims, Prosecution History Estoppel, Uncategorized | Leave a comment

ITC claim construction, written description, and finding of infringement by imported E. coli strains affirmed by Federal Circuit

Ajinomoto Co. et al. v. Int. Trade Commission (ITC) et al. Docket No. 2018-1590, -1629 (ITC No. 337-TA-1005) DYK (C/D), MOORE, TARANTO August 6, 2019 Brief Summary: ITC claim construction, written description, and finding that certain E. coli strains imported … Continue reading

Posted in Claim Construction, Doctrine of equivalents, Importation, Infringement, International Trade Commission, Prosecution History Estoppel, Uncategorized, Written description | Leave a comment

Federal Circuit affirmed DC claim construction finding that “100% by weight” limitation can include “residual moisture”

E.I. Du Pont De Nemours & Co. v. Unifrax I LLC Docket 2017-2575 O’MALLEY, REYNA, HUGHES April 17, 2019 Brief summary: DC finding that “platelets in an amount of 100% by weight” can include “some residual dispersant” and its denial … Continue reading

Posted in Anticipation (35 USC 102), Claim Construction, Conception and Reduction to Practice, Infringement | Leave a comment

Amgen, Inc. et al. v. Sandoz Inc. et al.

Docket Nos. 2018-1551 and -1552 LOURIE, O’MALLEY, REYNA May 8, 2019 Brief summary: DC claim construction findings and grant of SJ of non-infringement to Sandoz regarding its Neupogen® and Neulasta® biosimilars affirmed. Summary: Amgen appealed two DC decisions finding Sandoz’s … Continue reading

Posted in Biosimilars, Claim Construction, Collateral estoppel, Doctrine of equivalents, Generics / ANDA, Infringement | Leave a comment

Omega Patents, LLC v. CalAmp Corp.

Docket No. 2018-1309 PROST, DYK, WALLACH April 8, 2019 Brief summary: DC decision finding infringement of ‘727 claim 1 affirmed; others reversed and remanded for state of mind analysis and to determine whether there were predicate acts of infringement; willfulness … Continue reading

Posted in Attorney's Fees, Claim Construction, Damages, Inducement to Infringe, Infringement, Willfullness | Leave a comment